Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Aug 15;27(16):4478-4485.
doi: 10.1158/1078-0432.CCR-20-4557. Epub 2021 Mar 22.

FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer

Preeti Narayan  1 , Christy L Osgood  2 , Harpreet Singh  2 , Haw-Jyh Chiu  2 , Tiffany K Ricks  2 , Edwin Chiu Yuen Chow  2 , Junshan Qiu  2 , Pengfei Song  2 , Jingyu Yu  2 , Frances Namuswe  2 , Maria Guiterrez-Lugo  2 , Sherry Hou  2 , William F Pierce  2 , Kirsten B Goldberg  2   3 , Shenghui Tang  2 , Laleh Amiri-Kordestani  2 , Marc R Theoret  2   3 , Richard Pazdur  3 , Julia A Beaver  2   3
Affiliations
Randomized Controlled Trial

FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer

Preeti Narayan et al. Clin Cancer Res. .

Abstract

On December 20, 2019, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki [DS-8201a; T-DXd; tradename ENHERTU (Daiichi Sankyo)] for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. Approval was based on data from study DS8201-A-U201 (DESTINY-Breast01) with supportive safety data from study DS8201-A-J101. The primary efficacy endpoint in DESTINY-Breast01 was overall response rate (ORR) based on confirmed responses by blinded independent central review (ICR) using RECIST v1.1 in all participants who were assigned to receive the recommended dose of 5.4 mg/kg while secondary endpoints included duration of response (DoR). The confirmed ORR based on ICR in these 184 patients was 60.3% [95% confidence interval (CI): 52.9-67.4] and the median DoR was 14.8 months (95% CI: 13.8-16.9). Interstitial lung disease, including pneumonitis, was experienced in patients treated with T-DXd and can be severe, life threatening, or fatal. In addition, neutropenia and left ventricular dysfunction were included as Warnings and Precautions in labeling. Other important common adverse reactions were nausea, fatigue, vomiting, alopecia, constipation, decreased appetite, anemia, diarrhea, and thrombocytopenia. Overall, the totality of efficacy and safety data supported the accelerated approval of T-DXd for the intended indication.

PubMed Disclaimer

Conflict of interest statement

Disclosure of Potential Conflicts of Interest: The authors report no financial interests or relationships with the commercial sponsors of any products discussed in this report.

Figures

Figure 1:
Figure 1:
Structure of Fam-Trastuzumab Deruxtecan-nxki (15)
See this image and copyright information in PMC

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394–424. - PubMed
    1. National Cancer Institute. Surveillance, Epidemiology and End Results Program (SEER). Female Breast Cancer. [cited 2020 Jul 2]. Available from: https://seer.cancer.gov/statfacts/html/breast.html
    1. American Cancer Society. Key Statistics for Breast Cancer in Men. [cited 2020 Jul 2]. Available from: https://www.cancer.org/cancer/breast-cancer-in-men/about/key-statistics....
    1. National Cancer Institute. Surveillance, Epidemiology and End Results Program (SEER). Female Breast Cancer Subtypes. [cited 2020 Jun 2]. Available from: https://seer.cancer.gov/statfacts/html/breast-subtypes.html
    1. Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LAG, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014; 106(5): dju055 doi:10.1093/jnci/dju055. - DOI - PMC - PubMed

Publication types